PT Kalbe Farma TbkFRA:LCLA -29.79%77 PB Ratio is 1.24 as of Jun. 26, 2026, which is 70% below its 10-year median of 4.20. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks better than 60.52% on this metric.
PT Kalbe Farma Tbk stock PB Ratio (=1.3) is close to 10-year low of 1.29.
The historical rank and industry rank for PT Kalbe Farma Tbk's PB Ratio or its related term are showing as below:
FRA:LCLA'
s PB Ratio Range Over the Past 10 Years
Min: 1.29 Med: 4.2 Max: 7.79
Current: 1.91
During the past 13 years, PT Kalbe Farma Tbk's highest PB Ratio was 7.79. The lowest was 1.29. And the median was 4.20.
FRA:LCLA's PB Ratio is ranked better than 60.52% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs FRA:LCLA: 1.91
During the past 12 months, PT Kalbe Farma Tbk's average Book Value Per Share Growth Rate was 4.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PT Kalbe Farma Tbk was 20.60% per year. The lowest was 5.30% per year. And the median was 13.15% per year.
Back to Basics: PB Ratio
PT Kalbe Farma Tbk (FRA:LCLA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PT Kalbe Farma Tbk PB Ratio Related Terms
PT Kalbe Farma Tbk PB Ratio Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's PB Ratio distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PT Kalbe Farma Tbk (FRA:LCLA) has a PB Ratio of 1.24 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PT Kalbe Farma Tbk and its competitors. This is 70% below median its historical median of 4.20. Over the past decade, PT Kalbe Farma Tbk's PB Ratio has ranged from 1.29 to 7.79. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #364 out of 922 companies in the Drug Manufacturers industry, placing it in the top 39.5%.
Is PT Kalbe Farma Tbk's PB Ratio too high?
PT Kalbe Farma Tbk's current PB Ratio of 1.24 is 70% below median its 10-year median of 4.20. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 7.79. The Drug Manufacturers industry median PB Ratio is 1.83. PT Kalbe Farma Tbk's value of 1.24 is 32.1% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #364 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #364 out of 922 companies for PB Ratio. This puts PT Kalbe Farma Tbk in the upper half of its industry. The industry median PB Ratio is 1.83. PT Kalbe Farma Tbk's value of 1.24 is 32.1% below this benchmark. Historically, PT Kalbe Farma Tbk's own PB Ratio has ranged from 1.29 to 7.79 over the past decade. While the company's 10-year median is 4.20 vs. the industry median of 1.83, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current PB Ratio of 1.24 is 32.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current PB Ratio is 1.24, which is 70% below median its own 10-year median of 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.03 — trading 52.1% below its estimated fair value. The current PB Ratio is 1.24, which is 70% below median its 10-year median of 4.20 and 32.1% below the Drug Manufacturers industry median of 1.83. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current PB Ratio is 1.24 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.03 is trading 52.1% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
PB Ratio: 1.24 (70% below median its 10-year median of 4.20)
GF Value™: €0.07 vs. price of €0.03 (52.1% below fair value)
Industry Position: 32.1% below the Drug Manufacturers median (#364 of 922)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
